Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
$13.17
+0.4%
$11.51
$6.64
$35.52
$12.87M1.87479,845 shs17,400 shs
LLIT
Lianluo Smart
$0.79
$9.91
$2.76
$17.14
$1.74M0.161.04 million shs117,181 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.41
+1.8%
$3.87
$2.70
$11.55
$8.60M2.2628,700 shs7,134 shs
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
$0.58
$0.22
$2.40
$997K0.658.25 million shs1.89 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00%0.00%0.00%0.00%0.00%
LLIT
Lianluo Smart
-2.07%+7.82%-14.55%-3.53%-22.92%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+1.85%+20.82%+8.89%+42.26%-60.77%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00%0.00%0.00%-53.25%-76.24%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A$4.77 per shareN/A
LLIT
Lianluo Smart
$380K4.57N/AN/A($0.59) per share-1.33
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.49N/AN/A$13.18 per share0.33
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A$6.48 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
-$5.62MN/A0.00N/AN/AN/AN/AN/A
LLIT
Lianluo Smart
-$4.45MN/A0.00N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/A

Latest NVIV, NURO, APOP, and LLIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
3.01
3.01
LLIT
Lianluo Smart
N/A
2.42
2.17
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/A
14.30
14.30

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
4.84%
LLIT
Lianluo Smart
28.75%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
13.78%

Insider Ownership

CompanyInsider Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
LLIT
Lianluo Smart
22.90%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
2.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
2,020977,000N/ANot Optionable
LLIT
Lianluo Smart
62.21 millionN/ANot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
63.11 million3.03 millionNot Optionable

NVIV, NURO, APOP, and LLIT Headlines

SourceHeadline
Interview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?Interview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?
outsourcing-pharma.com - April 8 at 7:38 PM
Gut health supplements are everywhere – but which are the best ones for *you*?Gut health supplements are everywhere – but which are the best ones for *you*?
msn.com - March 28 at 4:18 PM
Drug discovery and global player, Cresset, moves team into Boston marking major turning pointDrug discovery and global player, Cresset, moves team into Boston marking major turning point
outsourcing-pharma.com - March 12 at 7:43 PM
InVivo Therapeutics Holdings CorporationInVivo Therapeutics Holdings Corporation
cnn.com - February 15 at 12:40 AM
InVivo Therapeutics Holdings Corp.InVivo Therapeutics Holdings Corp.
wsj.com - February 14 at 2:40 PM
Firm Retention Summary: InVivo Therapeutics HoldingsFirm Retention Summary: InVivo Therapeutics Holdings
wsj.com - February 13 at 6:29 PM
InVivo Therapeutics Holdings Corp (NVIV)InVivo Therapeutics Holdings Corp (NVIV)
investing.com - February 7 at 11:49 PM
Bob Langer-founded device-maker declares bankruptcyBob Langer-founded device-maker declares bankruptcy
bizjournals.com - February 6 at 4:38 PM
Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today?Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today?
investorplace.com - February 6 at 9:12 AM
InVivo Therapeutics Shares Plumb New Depths After Bankruptcy FilingInVivo Therapeutics Shares Plumb New Depths After Bankruptcy Filing
marketwatch.com - February 1 at 2:09 PM
Spinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market InsightsSpinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market Insights
prnewswire.co.uk - January 31 at 12:06 PM
InVivo Therapeutics Holdings: Submission Of Matters To A Vote Of Security HoldersInVivo Therapeutics Holdings: Submission Of Matters To A Vote Of Security Holders
cbonds.com - January 5 at 10:04 AM
InVivo Biosystems Secures New Investment to Accelerate CRISPR InnovationInVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation
pharmiweb.com - January 4 at 1:33 PM
InVivo Therapeutics Holdings Corp NVIVInVivo Therapeutics Holdings Corp NVIV
morningstar.com - November 10 at 7:26 AM
Apollo, Nimbus lead bumper week for biotech financingsApollo, Nimbus lead bumper week for biotech financings
pharmaphorum.com - September 8 at 9:41 AM
Australia’s United Malt OKs $1-B takeover offer from France’s InVivoAustralia’s United Malt OKs $1-B takeover offer from France’s InVivo
business.inquirer.net - July 2 at 10:09 PM
Spinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030Spinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030
marketwatch.com - June 22 at 5:14 PM
Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate StrategyRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy
benzinga.com - May 1 at 12:30 PM
Why InVivo Therapeutics Shares Are Plunging TodayWhy InVivo Therapeutics Shares Are Plunging Today
finance.yahoo.com - March 17 at 1:53 AM
InVivo seeks longer-term control in Casino-Teract retail tie-upInVivo seeks longer-term control in Casino-Teract retail tie-up
msn.com - March 10 at 6:45 PM
Why Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving PremarketWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
msn.com - March 10 at 6:45 PM
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%
msn.com - March 10 at 3:10 AM
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursdays Mid-Day SessionWhy JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
msn.com - March 9 at 5:08 PM
InVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary EndpointInVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpoint
markets.businessinsider.com - March 9 at 5:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cellect Biotechnology logo

Cellect Biotechnology

NASDAQ:APOP
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Lianluo Smart

NASDAQ:LLIT
Lianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
InVivo Therapeutics logo

InVivo Therapeutics

NASDAQ:NVIV
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.